Press Releases for PPHM

Press Releases
Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
BenchmarkJournal.Com Free Analyst Review for GAP, ATU, PPHM, MNKD, HLIT and COCO
Peregrine Pharmaceuticals to Report Fiscal Year 2009 Financial Results
Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer
Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule - Mar 25 2009 8:28AM
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2009
Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
Peregrine Pharmaceuticals Receives Notification of Extension to Regain Compliance With NASDAQ's Minimum Bid Price Rule
Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections
Avid Bioservices Expands Capabilities With Installation of Innovative Thermo Scientific HyClone Single-Use Bioreactor Systems
Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
Avid Bioservices to Serve as Contract Manufacturer for Catalyst Biosciences' Novel Human Coagulation Factor Clinical Candidate
Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule - Nov 11 2008 2:03AM
Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
Peregrine Pharmaceuticals' anti-PS Technology Platform to Be Discussed at AIDS Vaccine 2008 Conference
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
Nasdaq Panel Grants Peregrine Pharmaceuticals' Request for 180-Day Extension for Continued Listing on Nasdaq
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Peregrine Pharmaceuticals Receives Letter From NASDAQ Citing Failure to Regain Compliance With Minimum Bid Price Rule
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Peregrine Pharmaceuticals to Report Fiscal Year 2008 Financial Results
Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
DSM and Crucell Sign Agreement with Avid Bioservices to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6(R) Cell Line Proteins
Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
BellwetherReport.com Analyst Report on ACOR, CNXT, PPHM and ABMD
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Peregrine Pharmaceuticals Reports Studies Published in 'Science' Highlight Key Role of Phosphatidylserine (PS) in Viral Infections - Jun 2 2008 2:00AM
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies
Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting